acetazolamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	56	59-66-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acetazolamide acetamox acetazolamid cidamex nephramide acetazolamide sodium	One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Molecular weight: 222.24 Formula: C4H6N4O3S2 CLOGP: -0.98 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 115.04 ALOGS: -1.90 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acetazolamide
acetamox
acetazolamid
cidamex
nephramide
acetazolamide sodium

One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Molecular weight: 222.24
Formula: C4H6N4O3S2
CLOGP: -0.98
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 115.04
ALOGS: -1.90
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.75	g	O
0.75	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.64 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	75.14 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.37 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.65 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	13 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 27, 1953	FDA	TEVA BRANDED PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Idiopathic intracranial hypertension	170.28	17.06	45	8197	2886	63477894
Angle closure glaucoma	152.80	17.06	39	8203	2180	63478600
Papilloedema	134.78	17.06	40	8202	3920	63476860
Hair follicle tumour benign	133.77	17.06	26	8216	405	63480375
Metabolic acidosis	132.80	17.06	79	8163	44990	63435790
Intraocular pressure increased	114.00	17.06	39	8203	6039	63474741
Choroidal effusion	101.49	17.06	21	8221	455	63480325
Intracranial pressure increased	88.21	17.06	31	8211	5196	63475584
Off label use	86.92	17.06	236	8006	674226	62806554
Choroidal detachment	72.15	17.06	14	8228	216	63480564
Complications of bone marrow transplant	56.74	17.06	13	8229	458	63480322
Hepatosplenic T-cell lymphoma	53.55	17.06	13	8229	590	63480190
Glaucoma	50.13	17.06	31	8211	18874	63461906
Retinal detachment	49.09	17.06	21	8221	5948	63474832
Macular detachment	43.09	17.06	8	8234	96	63480684
Acute generalised exanthematous pustulosis	42.19	17.06	23	8219	11076	63469704
Flat anterior chamber of eye	40.62	17.06	7	8235	53	63480727
Hypercapnia	37.83	17.06	17	8225	5414	63475366
Corneal oedema	37.71	17.06	12	8230	1481	63479299
Aggression	37.16	17.06	28	8214	23470	63457310
Photophobia	37.09	17.06	25	8217	17610	63463170
Intellectual disability	37.08	17.06	11	8231	1075	63479705
Drug ineffective	35.64	17.06	244	7998	1044521	62436259
Visual impairment	35.42	17.06	49	8193	84397	63396383
Hypotony of eye	33.94	17.06	7	8235	149	63480631
Sickle cell anaemia with crisis	33.15	17.06	16	8226	5987	63474793
Visual field defect	31.80	17.06	16	8226	6545	63474235
Ophthalmic vein thrombosis	31.36	17.06	7	8235	219	63480561
Lens dislocation	29.61	17.06	5	8237	33	63480747
Myopia	28.63	17.06	10	8232	1645	63479135
Haemorrhagic diathesis	28.16	17.06	13	8229	4402	63476378
Drug ineffective for unapproved indication	28.13	17.06	28	8214	34035	63446745
Persecutory delusion	26.92	17.06	11	8231	2779	63478001
Cerebral venous sinus thrombosis	26.91	17.06	10	8232	1962	63478818
Retinopathy haemorrhagic	26.79	17.06	4	8238	10	63480770
Dysphoria	26.71	17.06	13	8229	4953	63475827
Psychiatric decompensation	26.30	17.06	9	8233	1392	63479388
Product contamination microbial	26.14	17.06	6	8236	213	63480567
Myasthenic syndrome	25.12	17.06	6	8236	254	63480526
Joint space narrowing	24.66	17.06	7	8235	585	63480195
Iridocyclitis	24.53	17.06	10	8232	2512	63478268
Nephrocalcinosis	24.51	17.06	8	8234	1070	63479710
Retroperitoneal oedema	24.47	17.06	4	8238	21	63480759
Osteopenia	23.64	17.06	20	8222	19765	63461015
Toxic leukoencephalopathy	23.02	17.06	7	8235	744	63480036
CSF pressure increased	22.86	17.06	5	8237	142	63480638
Vision blurred	22.84	17.06	42	8200	91882	63388898
Transmission of an infectious agent via product	22.73	17.06	5	8237	146	63480634
Acute respiratory failure	22.50	17.06	25	8217	34460	63446320
Cross sensitivity reaction	22.50	17.06	9	8233	2153	63478627
Ocular surface disease	22.21	17.06	4	8238	40	63480740
Appetite disorder	21.97	17.06	13	8229	7308	63473472
Overlap syndrome	21.80	17.06	7	8235	889	63479891
Endophthalmitis	21.13	17.06	10	8232	3582	63477198
Arthritis infective	20.75	17.06	12	8230	6466	63474314
Diplopia	20.51	17.06	20	8222	23708	63457072
Cataract	19.40	17.06	30	8212	57023	63423757
Hyphaema	19.33	17.06	5	8237	294	63480486
Oral pain	19.24	17.06	21	8221	28373	63452407
Acidosis	19.13	17.06	14	8228	11219	63469561
Non-cardiogenic pulmonary oedema	18.98	17.06	6	8236	725	63480055
Ocular pemphigoid	18.94	17.06	4	8238	96	63480684
Vitreous disorder	18.82	17.06	4	8238	99	63480681
Lactic acidosis	18.78	17.06	24	8218	38263	63442517
Hyperventilation	18.72	17.06	11	8231	6105	63474675
Optic disc haemorrhage	18.52	17.06	4	8238	107	63480673
Conjunctival hyperaemia	18.35	17.06	8	8234	2371	63478409
Meningitis aseptic	18.34	17.06	10	8232	4813	63475967
Bacterial endophthalmitis	18.21	17.06	4	8238	116	63480664
Nasal flaring	17.87	17.06	3	8239	19	63480761
Optic neuritis	17.83	17.06	12	8230	8423	63472357
Hypersensitivity	17.59	17.06	8	8234	292677	63188103
Retinal vascular occlusion	17.57	17.06	5	8237	422	63480358
Product use in unapproved indication	17.44	17.06	57	8185	179023	63301757
Swelling	17.39	17.06	7	8235	275371	63205409
Foetal exposure during pregnancy	17.22	17.06	21	8221	31941	63448839
Skin warm	17.15	17.06	10	8232	5466	63475314
Rhinocerebral mucormycosis	17.15	17.06	5	8237	460	63480320

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	176.16	19.31	51	3872	5332	34947676
Metabolic acidosis	132.38	19.31	74	3849	43606	34909402
Choroidal detachment	131.85	19.31	25	3898	397	34952611
Angle closure glaucoma	95.26	19.31	22	3901	935	34952073
Toxic epidermal necrolysis	91.96	19.31	46	3877	21600	34931408
Choroidal effusion	83.16	19.31	15	3908	178	34952830
Drug ineffective	53.98	19.31	141	3782	456610	34496398
Congenital emphysema	48.58	19.31	6	3917	0	34953008
Intraocular pressure decreased	47.09	19.31	8	3915	65	34952943
Hyphaema	45.38	19.31	11	3912	576	34952432
Drug reaction with eosinophilia and systemic symptoms	45.19	19.31	34	3889	32978	34920030
Glaucoma	42.59	19.31	19	3904	6893	34946115
Visual acuity reduced	42.49	19.31	25	3898	16124	34936884
Corneal oedema	40.63	19.31	12	3911	1339	34951669
Ocular surface disease	39.63	19.31	7	3916	73	34952935
Off label use	36.30	19.31	116	3807	419408	34533600
Burkholderia test positive	30.38	19.31	9	3914	1014	34951994
Hypochloraemia	29.72	19.31	8	3915	637	34952371
Idiopathic intracranial hypertension	29.06	19.31	8	3915	693	34952315
Respiratory acidosis	28.31	19.31	13	3910	5037	34947971
Photocoagulation	27.99	19.31	4	3919	8	34953000
Acidosis hyperchloraemic	27.69	19.31	7	3916	436	34952572
Crystalluria	27.12	19.31	7	3916	474	34952534
Corneal opacity	25.75	19.31	7	3916	579	34952429
Product contamination microbial	24.92	19.31	7	3916	653	34952355
Trabeculectomy	24.90	19.31	4	3919	22	34952986
Visual impairment	22.96	19.31	24	3899	35778	34917230
Hypocapnia	22.72	19.31	5	3918	170	34952838
Transmission of an infectious agent via product	22.36	19.31	5	3918	183	34952825
Visual acuity tests abnormal	21.98	19.31	4	3919	50	34952958
Acute kidney injury	21.56	19.31	79	3844	304909	34648099
Bacterial endophthalmitis	21.06	19.31	4	3919	64	34952944
Hypercapnia	20.91	19.31	10	3913	4245	34948763
Dysmetria	20.89	19.31	6	3917	606	34952402
Endophthalmitis	19.57	19.31	9	3914	3499	34949509
Respiratory distress	19.54	19.31	22	3901	35643	34917365

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angle closure glaucoma	240.20	15.37	60	10840	2916	79730572
Intraocular pressure increased	212.79	15.37	70	10830	9135	79724353
Choroidal detachment	211.57	15.37	41	10859	595	79732893
Metabolic acidosis	177.93	15.37	121	10779	82408	79651080
Choroidal effusion	172.89	15.37	35	10865	642	79732846
Idiopathic intracranial hypertension	149.94	15.37	42	10858	3180	79730308
Hair follicle tumour benign	136.20	15.37	27	10873	443	79733045
Off label use	108.19	15.37	319	10581	906896	78826592
Papilloedema	99.68	15.37	36	10864	6197	79727291
Intracranial pressure increased	82.70	15.37	34	10866	8288	79725200
Drug ineffective	71.76	15.37	314	10586	1080599	78652889
Toxic epidermal necrolysis	70.01	15.37	54	10846	44527	79688961
Corneal oedema	68.97	15.37	22	10878	2598	79730890
Glaucoma	67.89	15.37	39	10861	19722	79713766
Hyphaema	61.95	15.37	16	10884	888	79732600
Ocular surface disease	60.34	15.37	11	10889	112	79733376
Hypercapnia	57.84	15.37	27	10873	8908	79724580
Complications of bone marrow transplant	51.99	15.37	13	10887	633	79732855
Retinal detachment	50.91	15.37	25	10875	9222	79724266
Transmission of an infectious agent via product	49.00	15.37	10	10890	191	79733297
Hepatosplenic T-cell lymphoma	48.03	15.37	13	10887	865	79732623
Product contamination microbial	47.07	15.37	13	10887	933	79732555
Visual impairment	44.81	15.37	59	10841	92072	79641416
Visual acuity reduced	44.75	15.37	35	10865	29434	79704054
Photophobia	43.92	15.37	30	10870	20498	79712990
Macular detachment	42.07	15.37	9	10891	218	79733270
Drug reaction with eosinophilia and systemic symptoms	40.69	15.37	47	10853	64197	79669291
Endophthalmitis	40.30	15.37	19	10881	6409	79727079
Flat anterior chamber of eye	39.14	15.37	8	10892	154	79733334
Bacterial endophthalmitis	38.30	15.37	8	10892	172	79733316
Ophthalmic vein thrombosis	36.01	15.37	8	10892	232	79733256
Visual field defect	34.16	15.37	19	10881	9026	79724462
Myopia	33.92	15.37	12	10888	1944	79731544
Vision blurred	32.97	15.37	55	10845	105843	79627645
Corneal opacity	32.87	15.37	10	10890	1010	79732478
Intraocular pressure decreased	32.51	15.37	7	10893	175	79733313
Acidosis hyperchloraemic	30.35	15.37	9	10891	833	79732655
Hypotony of eye	30.07	15.37	7	10893	251	79733237
Acute generalised exanthematous pustulosis	29.50	15.37	22	10878	17232	79716256
Non-cardiogenic pulmonary oedema	29.09	15.37	10	10890	1489	79731999
Acidosis	28.98	15.37	23	10877	19739	79713749
Retinal vascular occlusion	28.64	15.37	8	10892	599	79732889
Cerebral venous sinus thrombosis	28.47	15.37	11	10889	2280	79731208
Sickle cell anaemia with crisis	28.18	15.37	16	10884	7906	79725582
Hypocapnia	28.18	15.37	8	10892	635	79732853
Trabeculectomy	27.16	15.37	5	10895	54	79733434
Photocoagulation	26.58	15.37	4	10896	10	79733478
Iridocyclitis	26.50	15.37	12	10888	3692	79729796
Crystalluria	25.09	15.37	8	10892	943	79732545
Vitreous disorder	24.79	15.37	6	10894	255	79733233
Retroperitoneal oedema	24.27	15.37	4	10896	21	79733467
Osteopenia	24.03	15.37	20	10880	18344	79715144
Dysphoria	23.70	15.37	12	10888	4722	79728766
Joint space narrowing	23.27	15.37	7	10893	681	79732807
Respiratory acidosis	23.09	15.37	16	10884	11184	79722304
Eye pain	22.96	15.37	27	10873	37551	79695937
Intellectual disability	22.52	15.37	8	10892	1312	79732176
Lens dislocation	22.18	15.37	5	10895	155	79733333
Diplopia	22.05	15.37	25	10875	33441	79700047
Cataract	21.69	15.37	34	10866	62086	79671402
Multiple-drug resistance	21.56	15.37	14	10886	8794	79724694
Corneal disorder	21.54	15.37	9	10891	2282	79731206
Nephrocalcinosis	21.51	15.37	8	10892	1494	79731994
Somnolence	20.93	15.37	76	10824	238905	79494583
Haemorrhagic diathesis	20.87	15.37	12	10888	6072	79727416
Aggression	20.80	15.37	30	10870	50928	79682560
Punctate keratitis	20.79	15.37	7	10893	979	79732509
Appetite disorder	20.68	15.37	13	10887	7726	79725762
Overlap syndrome	20.53	15.37	7	10893	1017	79732471
Drug resistance	20.46	15.37	27	10873	42186	79691302
Burkholderia test positive	19.99	15.37	6	10894	579	79732909
CSF pressure increased	19.79	15.37	5	10895	254	79733234
Retinopathy haemorrhagic	19.72	15.37	4	10896	74	79733414
Meningitis aseptic	19.43	15.37	12	10888	6916	79726572
Conjunctival hyperaemia	18.69	15.37	10	10890	4403	79729085
Prostaglandin analogue periorbitopathy	18.67	15.37	3	10897	13	79733475
Acute respiratory failure	18.62	15.37	31	10869	59510	79673978
Blindness	18.36	15.37	21	10879	28362	79705126
Product use in unapproved indication	18.15	15.37	75	10825	250284	79483204
Hyperventilation	17.98	15.37	12	10888	7887	79725601
Visual acuity tests abnormal	17.94	15.37	4	10896	118	79733370
Myasthenic syndrome	17.84	15.37	6	10894	836	79732652
Intraventricular haemorrhage	17.73	15.37	10	10890	4877	79728611
Persecutory delusion	17.69	15.37	10	10890	4899	79728589
Brain stem haematoma	17.65	15.37	4	10896	127	79733361
Arthritis infective	17.48	15.37	12	10888	8259	79725229
Optic disc haemorrhage	17.39	15.37	4	10896	136	79733352
Vitreous haemorrhage	17.39	15.37	9	10891	3704	79729784
Neutropenia	17.10	15.37	9	10891	287701	79445787
Retinopathy	16.99	15.37	9	10891	3882	79729606
Psychiatric decompensation	16.84	15.37	9	10891	3954	79729534
Anterior chamber disorder	16.81	15.37	4	10896	158	79733330
Presyncope	16.51	15.37	24	10876	41030	79692458
Drug ineffective for unapproved indication	16.46	15.37	27	10873	51211	79682277
Dysmetria	16.43	15.37	6	10894	1065	79732423
Respiratory alkalosis	16.13	15.37	9	10891	4302	79729186
Iris adhesions	16.10	15.37	5	10895	541	79732947
Blepharitis	15.87	15.37	8	10892	3116	79730372
Drug clearance decreased	15.40	15.37	8	10892	3319	79730169

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EC01	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors
FDA CS	M0020790	Sulfonamides
FDA MoA	N0000000235	Carbonic Anhydrase Inhibitors
FDA EPC	N0000175517	Carbonic Anhydrase Inhibitor
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002257	Carbonic Anhydrase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004232	Diuretics
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D045283	Natriuretic Agents
CHEBI has role	CHEBI:23018	EC 4.2.1.1 inhibitor
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:35623	anticonvulsants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant glaucoma	indication	10100008
Anoxia due to high altitude	indication	42883007
Absence seizure	indication	79631006
Open-angle glaucoma	indication	84494001	DOID:1067
Secondary glaucoma	indication	95717004
Edema	indication	267038008
Peripheral edema	indication	271809000
Angle-closure glaucoma	indication	392291006	DOID:13550
Peripheral Edema due to Chronic Heart Failure	indication
Metabolic alkalosis	off-label use	1388004
Myoclonic seizure	off-label use	37356005
Idiopathic intracranial hypertension	off-label use	68267002	DOID:11459
Benign intracranial hypertension	off-label use	68267002	DOID:11459
Familial hypokalemic periodic paralysis	off-label use	82732003	DOID:14452
Epilepsy	off-label use	84757009	DOID:1826
Obstructive hydrocephalus	off-label use	230746009	DOID:14159
Familial periodic paralysis	off-label use	267607008	DOID:1029
Tonic-clonic epilepsy	off-label use	352818000	DOID:7725
Simple partial seizure	off-label use	117891000119100
Urine Alkalinization	off-label use
Hydrocephalus due to Intraventricular Hemorrhage	off-label use
Mixed Epilepsy	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Respiratory acidosis	contraindication	12326000
Hyperkalemia	contraindication	14140009
Metabolic acidosis, normal anion gap, acidifying salts	contraindication	18104000
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Decreased respiratory function	contraindication	80954004
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Disorder of electrolytes	contraindication	237840007
Primary adrenocortical insufficiency	contraindication	373662000
Recurrent Calcium Renal Calculi	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Mild congestive heart failure	Indication
Dogs	Rapid reduction of intraocular pressure	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Vetamox Soluble Powder	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.04	acidic
pKa2	9.21	acidic
pKa3	1.84	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN	INHIBITOR	Ki	8.60	CHEMBL	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	INHIBITOR	Ki	7.92	CHEMBL	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN	INHIBITOR	Ki	7.96	CHEMBL	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN	INHIBITOR	Ki	8.48	CHEMBL	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	7.22	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	7.27	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.60	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	8.51	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	7.96	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	7.39	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	8.24	CHEMBL
Carbonic anhydrase	Enzyme	O43570 P00915 P00918 P07451 P22748 P23280 P35218 P43166 Q16790 Q8N1Q1 Q9ULX7 Q9Y2D0	CAH12_HUMAN CAH1_HUMAN CAH2_HUMAN CAH3_HUMAN CAH4_HUMAN CAH6_HUMAN CAH5A_HUMAN CAH7_HUMAN CAH9_HUMAN CAH13_HUMAN CAH14_HUMAN CAH5B_HUMAN		Ki	9.10	CHEMBL
Carbonic anhydrase V	Enzyme	P35218 Q9Y2D0	CAH5A_HUMAN CAH5B_HUMAN		Ki	8.74	CHEMBL
Carbonic anhydrase-related protein 11	Enzyme	O75493	CAH11_HUMAN		Ki	8.24	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	8.05	CHEMBL
Aquaporin-1	Transporter	P29972	AQP1_HUMAN				WOMBAT-PK
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	7.70	CHEMBL
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE		Ki	7.77	CHEMBL
Carbonic anhydrase 4	Enzyme		CAH4_BOVIN		Ki	7.15	CHEMBL
Carbonic anhydrase 7	Enzyme		CAH7_MOUSE		Ki	7.80	CHEMBL
Carbonic anhydrase	Enzyme		CAH_METTE		Ki	7.22	CHEMBL
Carbonic anhydrase	Enzyme		Q50565_METTH		Ki	4.92	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	7.14	CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	7.09	CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	7.40	CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase	Enzyme		P96878_MYCTU		Ki	7.92	CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	7.96	CHEMBL
Alpha carbonic anhydrase	Enzyme		B5SU02_9CNID		Ki	7.80	CHEMBL
Endochitinase	Enzyme		CHIT_YEAST		Ki	4.68	CHEMBL
Carbonic anhydrase	Enzyme		C0IX24_9CNID		Ki	7.13	CHEMBL
Carbonic anhydrase 2	Enzyme		Q3I4V7_CRYNV		Ki	8	CHEMBL
Carbonic anhydrase	Enzyme		Q2PCB5_DICLA		Ki	5.24	CHEMBL
Astrosclerin-3	Enzyme		A6YCJ1_9METZ		Ki	7.29	CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	6.60	CHEMBL
Delta carbonic anhydrase	Unclassified		Q5U9J1_THAWE		Ki	7.08	CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	8.05	CHEMBL
Carbonic anhydrase 2	Enzyme		CAH2_BOVIN		IC50	6.02	CHEMBL
Carbonic anhydrase	Enzyme		CAH2_BOVIN CAH6_BOVIN CAH3_BOVIN CAH4_BOVIN		IC50	7.80	CHEMBL
Carbonic anhydrase	Enzyme		CAHX_FLABI		Ki	7.57	CHEMBL
Carbonic anhydrase 3	Enzyme		CAH3_BOVIN		Ki	4.08	CHEMBL
Carbonic anhydrase	Enzyme		Q5TU56_ANOGA		Ki	7.56	CHEMBL
Carbonic anhydrase	Enzyme		Q9HVB9_PSEAE		Ki	7.12	CHEMBL
Carbonic anhydrase, alpha family	Unclassified		Q31FD6_HYDCU		Ki	8.37	CHEMBL
Carbonate dehydratase	Enzyme		B2V8E3_SULSY		Ki	8.35	CHEMBL
Carbonic anhydrase 2, isoform A; LD26647p	Enzyme		Q9VTU8_DROME		Ki	7.11	CHEMBL
Carbonic anhydrase 1; GH09688p	Enzyme		Q9V396_DROME		Ki	6.97	CHEMBL

External reference:

ID	Source
4017898	VUID
N0000146250	NUI
D00218	KEGG_DRUG
1424-27-7	SECONDARY_CAS_RN
167	RXNORM
C0000981	UMLSCUI
CHEBI:27690	CHEBI
AZM	PDB_CHEM_ID
CHEMBL20	ChEMBL_ID
DB00819	DRUGBANK_ID
CHEMBL1200814	ChEMBL_ID
D000086	MESH_DESCRIPTOR_UI
1986	PUBCHEM_CID
6792	IUPHAR_LIGAND_ID
481	INN_ID
O3FX965V0I	UNII
33664007	SNOMEDCT_US
372709008	SNOMEDCT_US
72469007	SNOMEDCT_US
4017898	VANDF
4017899	VANDF
2596	MMSL
4121	MMSL
814	MMSL
d00161	MMSL
002286	NDDF
002287	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9006	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1050	TABLET	250 mg	ORAL	ANDA	19 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6663	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6663	TABLET	250 mg	ORAL	ANDA	18 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-567	TABLET	250 mg	ORAL	ANDA	18 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	10135-772	TABLET	125 mg	ORAL	ANDA	19 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	10135-773	TABLET	250 mg	ORAL	ANDA	19 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	16729-331	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	21 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	16729-331	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	21 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-120	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	11 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-313	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	16 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-313	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	16 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-787	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	12 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-787	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	12 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-787	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	12 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-831	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	16 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-831	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	16 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	29033-030	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	22 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	29033-030	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	22 sections